Skip to main content
. 2022 Jan 20;15:10. doi: 10.1186/s13048-022-00944-y

Fig. 9.

Fig. 9

Drug sensitivity analysis in different risk groups based on FIRLs signature. a IC50 levels of Docetaxel; b IC50 levels of Doxorubicin; c IC50 levels of Etoposide; d IC50 levels of Paclitaxel; e IC50 levels of Gemcitabine; f IC50 levels of Bleomycin; g IC50 levels of Cisplatin